研究单位：[1]EMD Serono ( EMD Serono Research & Development Institute,Inc. )[2]West China Hospital,Sichuan University Chengdu,China,610041[3]Sichuan Cancer Hospital Chengdu,China,610041[4]National Cancer Institute Bethesda,Maryland,United States,20892[5]Cancer & Hematology Centers of Western Michigan Grand Rapids,Michigan,United States,49546[6]MidAmerica Cancer Care Kansas City,Missouri,United States,64114[7]Southeastern Medical Oncology Center Goldsboro,North Carolina,United States,27534[8]FirstHealth of the Carolinas,Inc. Pinehurst,North Carolina,United States,28374[9]Summa Health Akron,Ohio,United States,44304[10]Toledo Clinic Toledo,Ohio,United States,43623
研究目的：
The main purpose of this study is to assess efficacy,safety,tolerability and pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with relapsed,platinum-resistant small-cell lung cancer (SCLC). This study will be conducted in two parts: safety run-in part and main part. The safety run-in part will be conducted in Japan.
